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Case report
Giant cell carcinoma of the lung successfully treated with surgical resection
and adjuvant vinorelbine and cisplatin
Saad Habiba,∗, Lazer Ezriel Leifera, Mohammed Azama, Abdul Hasan Siddiquib,
Kartikeya Rajdeva, Michel Chalhoubb
a Department of Internal Medicine, Northwell Health, Staten Island University Hospital, USA
bDepartment of Pulmonary and Critical Care, Northwell Health, Staten Island University Hospital, USA
A B S T R A C T
Giant Cell Carcinoma of the lung, a subtype of Sarcomatoid lung cancer is a poorly diﬀerentiated Non-Small-Cell Lung Cancer. GCCL has exceptionally aggressive
characteristics, and its prognosis is much poorer than any other NSCLCs. Herein, we present a rare case of Giant Cell Carcinoma of lung treated successfully with
surgical resection and adjuvant vinorelbine and cisplatin.
A 48-year-old African American man with a history of smoking and chronic obstructive pulmonary disease was admitted to the hospital for chief complaints of
shortness of breath. He was found to have a 3.5 cm×3.3 cm x 2.8 cm cavitary right upper lobe mass which turned out to be poorly diﬀerentiated Giant Cell
Carcinoma with extensive necrosis and deemed similar to stage 1b non-small cell lung cancer. He was successfully treated with right upper lobectomy and adjuvant
chemotherapy with vinorelbine and cisplatin. He was followed for seven years with no evidence of recurrent disease.
Giant Cell Carcinoma's existing literature is limited, and hence our case is reportable. Our case is unique because of the better outcome which we believe might be
the result of early detection and treatment with surgical resection along with adjuvant chemotherapy. More studies are needed to deeply understand the need for
adjuvant chemotherapy in stage 1 b GCCL, and proper guidelines are required for the indications of adjuvant chemotherapy in Stage 1b GCCL.
1. Introduction
Lung cancer is still the leading cause of cancer-related deaths, ac-
counting for 1.4 million deaths worldwide [1] and approximately
160,000 deaths in the United States every year [1] with increasing
incidence worldwide [2]. Giant cell carcinoma of the lung (GCCL) is a
rare variant of non-small cell lung carcinoma (NSCLC), accounting for
0.1–0.4% of all lung cancers [3]. It is clinically aggressive with in-
adequate response to antitumor chemotherapy, resulting in a very poor
prognosis [4]. Herein, we present a rare case of Giant Cell Carcinoma of
lung treated successfully with surgical resection and adjuvant vinor-
elbine and cisplatin.
1.1. Case presentation
Seven years ago, a 48-year-old African American man was admitted
to the hospital for concerns of shortness of breath and anxiety. Medical
history was signiﬁcant for 15-pack-year smoking history, Chronic
Obstructive Pulmonary Disease, anxiety, and osteoarthritis. On ima-
ging, chest x-ray showed an opacity in the right upper lobe. Subsequent
imaging of chest showed the presence of 3.5 cm×3.3 cm x 2.8 cm
cavitary right upper lobe mass with maximum SUV 5.0. He underwent a
bone scan which showed multiple foci of increased uptake through the
ribs and an intense focus in the right scapula which were non-FDG avid
on Positron emission tomography. The patient denied any family his-
tory of lung cancer.
A biopsy of the right lung mass was done which showed giant cell
carcinoma, poorly diﬀerentiated with extensive necrosis. The tumor
stage was T2N0Mx, equal to stage 1b non-small cell lung cancer.
Subsequently, the patient underwent right upper lobectomy with
mediastinal lymph node dissection and received four cycles of adjuvant
chemotherapy with vinorelbine and cisplatin. Eventually, the patient
quit smoking and was successfully treated with no evidence of recur-
rence on further imaging and follow up.
The patient was followed for seven years, and on imaging, multiple
stable rib lesions and right scapular bone lesions were seen. Subsequent
imaging with Computed Tomography of the chest showed no evidence
of parenchymal mass (Figs. 1 and 2). A biopsy of the rib lesion was
deferred by interventional radiology due to low yield and the risk of
causing pneumothorax. The oncology team concluded that the rib le-
sions and right scapular lesion were not of malignant etiology. Future
Computed tomography and Positron emission tomography scans were
negative for lymph nodes or any other organ involvement. He did well
so far, showing no local recurrence or distal disease in a 7-year follow-
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Giant Cell Carcinoma of the lung's existing literature is limited, and
the current NSCLC's general literature guides the current management.
Our patient's Giant Cell Carcinoma of lung was treated successfully with
surgical resection and adjuvant vinorelbine and cisplatin. Giant cell
carcinoma of the lung was ﬁrst discovered and named by Nash and
Stout in 1958 [5]. Giant Cell Carcinoma has been categorized by the
World Health Organization as a sarcomatoid carcinoma [3], along with
other subtypes, including pleomorphic carcinoma, spindle cell carci-
noma, carcinosarcoma, and pulmonary blastoma [3]. GCCL is diﬀerent
from Large Cell Carcinoma of the lung which is also a subtype of NSCLC
[6]. GCCL is associated with smoking, and it is more commonly seen in
males [5]. GCCL can occur in any lung lobe, but it is more commonly
found in the upper lobes [7]. GCCL may be asymptomatic like other
NSCLCs, or patients may complain of non-speciﬁc signs and symptoms
like cough or hemoptysis [7]. GCCL is a poorly diﬀerentiated tumor
with early metastasis to the brain, bone, adrenal gland, and liver,
through lymph and blood circulation. Uncommon metastasis to the
gastrointestinal tract, kidney, and heart has also been reported [7].
The majority of patients with suspected lung cancer require tissue
biopsy to conﬁrm the diagnosis [8]. GCCL is easily distinguished from
other forms of lung cancers by histopathology [3]. Under the micro-
scope, GCCL tumor cells are big, multi-core, bizarre with plenty of
neutrophils and lymphocytes in the background [7]. A characteristic
feature of GCCL is emperipolesis, which is the presence of collections of
polymorphonuclear leukocytes within the giant cells, apparently pha-
gocytosing cytoplasmic contents [7].
Surgical resection is an eﬀective treatment and provides adequate
control for limited-stage GCCL [7]. Patients with NSCLC are at sub-
stantial risk for recurrence and death even after complete surgical re-
section [9]. The role of adjuvant chemotherapy for patients with re-
sected stage IB disease is controversial [2]. However, in general
chemotherapy is oﬀered to medically appropriate patients with stage IB
disease whose tumors display one or more high-risk features, including
lymphovascular invasion, poor diﬀerentiation, high standardized
Fig. 1. Chest x-ray obtained two years and seven years after surgical resection of the right upper lobe showing no evidence of recurrence.
Fig. 2. Computer Tomography of chest post right upper lobe resection.
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uptake value (SUV) on positron emission tomography (PET; variably
deﬁned as SUV 10 or more). In our patient, adjuvant therapy with
cisplatin and vinorelbine was preferred due to the presence of a poorly
diﬀerentiated tumor. Adjuvant chemotherapy in stage IB disease with
tumor size> 4 cm may also improve survival [2]. The primary goal of
adjuvant therapy is to eradicate micrometastases, decreasing the rate of
distant metastases and, thereby, increasing survival following resection
[2]. In patients with stages IIA, IIB, and IIIA after complete resection,
adjuvant cisplatin-based chemotherapy has become a standard of care
[2]. Adjuvant cisplatin-based doublet therapy, preferably with vinor-
elbine is recommended currently and has been documented to show the
longest survival [2]. The eﬃcacy of radiotherapy in the treatment of
GCCL has not been identiﬁed yet [7].
In an assessment of a small number of NSCLC patients with epi-
dermal growth factor receptor (EGFR) mutations and anaplastic lym-
phoma kinase (ALK) inversions/translocations, EGFR tyrosine kinase
inhibitors were eﬀective in GCCL patients with EGFR mutations [4], but
the information about these mutations in GCCL is limited [4]. In GCCL
patients with positive expression of PD-L1, Pembrolizumab (anti-PDL1
antibody) has been reported to be eﬀective [4], although the data on
PD-L1 expression in GCCL is limited [4]. When compared with other
NSCLCs, GCCL has a poor prognosis with median survival reported to
be around 8–10 months [10]. Local or regional recurrence in stage I
NSCLC after surgical resection has been reported to be between 7% and
15% [11] and hence the role of adjuvant chemotherapy in stage 1b
GCCL speciﬁcally should be investigated.
In conclusion, Giant Cell Carcinoma's existing literature is limited,
and hence our case is reportable. Giant Cell carcinoma of lung is a rare
disease with aggressive characteristics. It has a poor response to che-
motherapy, resulting in a poor prognosis. Our case is unique because of
the better outcome which we believe might be the result of early de-
tection and treatment with surgical resection along with adjuvant
chemotherapy. This case emphasizes the role of adjuvant chemotherapy
in stage IB disease. However, proper guidelines are needed for the in-
dications of adjuvant chemotherapy in Stage 1b GCCL.
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